SOD3 and Parkinson disease: Following treatment with nilotinib, we identified significant changes in expression of miRNAs that interact with SOD3 (hsa-miR-6794-5p), APP (hsa-miR-302c-3p), presenilin (hsa-miR-1233-5p, hsa-miR-6829-3p), BACE1 (hsa-miR-4531), BDNF (hsa-miR-1-3p), CYCS (hsa-miR-3925-3p, hsa-miR-454-5p, hsa-miR-6797-3p), TCERG1 (hsa-miR-4262), and HDAC (hsa-miR-4634, hsa-miR-6794-5p, hsa-miR-3189-3p, hsa-miR-326), genes associated with pathogenesis in such diseases as AD, PD, and Amyotrophic Lateral Sclerosis (ALS), in addition to HD, as shown in Figure S3.